{{Infobox disease
 | Name           = Autoimmune lymphoproliferative syndrome
 | Image          =
 | Caption        =
 | DiseasesDB     = 33425
 | DiseasesDB_mult = {{DiseasesDB2|33424}}
 | ICD10          =
 | ICD9           =
 | ICDO           =
 | OMIM           = 601859
 | OMIM_mult      = {{OMIM2|603909}}
 | MedlinePlus    =
 | eMedicineSubj  =
 | eMedicineTopic =
 | MeshID         =
}}
'''Autoimmune lymphoproliferative syndrome''' (ALPS) is a form of [[lymphoproliferative disorder]] (LPDs). It affects [[lymphocyte]] [[apoptosis]].<ref name="pmid18193364" /> It is a [[RASopathy]].

==Introduction==
Autoimmune Lymphoproliferative Syndrome is a rare disorder of abnormal [[lymphocyte]] survival caused by defective [[Fas receptor|Fas]] mediated [[apoptosis]].<ref name="pmid16522544" /> Normally, after infectious insult, the immune system down-regulates by increasing Fas expression on activated B and T lymphocytes and Fas-ligand on activated T lymphocytes. Fas and Fas-ligand interact to trigger the caspase cascade, leading to cell apoptosis. Patients with ALPS have a defect in this apoptotic pathway, leading to chronic non-malignant lymphoproliferation, autoimmune disease, and secondary cancers.<ref name="pmid19930184" />

==Genetics==

This condition is usually caused by mutations in the FAS gene. Rarely cases due to mutations in other genes including the 
FAS ligand gene have been reported.<ref name=Magerus-Chatinet2012>Magerus-Chatinet A, Stolzenberg MC, Lanzarotti N, Neven B, Daussy C, Picard C, Neveux N, Desai M, Rao M, Ghosh K, Madkaikar M, Fischer A, Rieux-Laucat F (2012) Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation. J Allergy Clin Immunol</ref>

==Clinical manifestations==
{{prose|section|date=December 2011}}
Lymphoproliferation: The most common clinical manifestation of ALPS is lymphoproliferation, affecting 100% of patients.
* [[Lymphadenopathy]]: >90% of patients present with chronic non-malignant lymphadenopathy. It can be mild to severe, affecting multiple nodal groups. Most commonly presents with massive non-painful hard cervical lymphadenopathy
* [[Splenomegaly]]: >80% of patients present with clinically identifiable splenomegaly. It can be massive.
* [[Hepatomegaly]]: 30-40% of patients have enlarged livers.
* Lymphoproliferation tends to present at a young age (median 11.5 months) and may improve with age.
Autoimmune disease: The second most common clinical manifestation and one that most often requires treatment.
* Autoimmune cytopenias: Most common. Can be mild to very severe. Can be intermittent or chronic.<ref name="pmid15542578" />
** Autoimmune Hemolytic Anemia
** Autoimmune [[Neutropenia]]
** Autoimmune [[Thrombocytopenia]]
* Other: Can affect any organ system similar to [[systemic lupus erythematosis]] (most rare affecting <5% of patients)
** Nervous: Autoimmune cerebellar [[ataxia]]; [[Guillain-Barre]]; [[Transverse myelitis]]
** GI: Autoimmune esophagitis, gastritis, colitis, hepatitis, pancreatitis
** Derm: Urticaria
** Pulmonary: [[Bronchiolitis obliterans]]
** Renal: Autoimmune glomerulonephritis, nephrotic syndrome
* Cancer: Secondary neoplasms affect approximately 10% of patients. True prevalence unknown as <20 reported cases of cancer. Most common EBER+ Non-Hodgkin's and [[Hodgkin's]] lymphoma
** Unaffected family members with genetic mutations are also at increased risk of developing cancer

==Laboratory manifestations==
{{prose|section|date=December 2011}}
* Elevated peripheral blood Double Negative T cells (DNTs)<ref name="pmid12139944" />
** Required for diagnosis
** Immunophenotype: CD3+/CD4-/CD8-/TCRalpha/beta+
** Measured by [[flow cytometry]]: Normal values <2.5% total T cells; <1% of total lymphocytes in peripheral blood
** Marked elevations >5% virtually pathognomonic for ALPS
** Mild elevations also found in other autoimmune diseases
** Thought to be cytotoxic T lymphocytes that have lost CD8 expression
** Unknown if driver of disease or epiphenomenon
** May be falsely elevated in setting of lymphopenia or falsely decreased with immunosuppressive treatment
* Defective in vitro Fas mediated apoptosis
** Required for diagnosis under old definition. Now can be used to make diagnosis; however, not required to make diagnosis.
** Time and labor intensive assay.
** T cells from patient and normal control supported in culture for >10 days with mitogen stimulation and IL-2 expansion and then exposed to anti-Fas IgM monoclonal antibody
** ALPS patient T cells: Do not die with anti-Fas monoclonal antibody exposure. Normal T cells from unaffected patient do.
** False negative in somatic Fas variant ALPS and FasL variant ALPS
* Genetic mutations in ALPS causative genes (see below)
* Biomarkers<ref name="pmid19176318" /><ref name="pmid20227752" />
** Polyclonal [[hypergammaglobulinemia]]<ref name="pmid20068224" />
** Elevated serum FASL
** Elevated plasma [[Interleukin 10|IL-10]] and/or IL-18
** Elevated plasma or serum [[vitamin B12]]
* [[Autoantibodies]]: Non-specific. Can have antibodies to blood cells (DAT, anti-neutrophil, anti-platelet). Also, can have positive ANA, RF, ANCA.

==Classification==
{{confusing|section|date=December 2011}}
Old nomenclature<ref name="pmid12819469" />
* IA - [[Fas receptor|Fas]]
* IB - [[Fas ligand]]
* IIA - [[Caspase 10]]
* IIB  - [[Caspase 8]]
* III - unknown
* IV - [[Neuroblastoma RAS viral oncogene homolog]]
Revised nomenclature (2010)<ref name="pmid20538792" />
* ALPS-FAS: Fas. Germline FAS mutations. 70% of patients. Autosomal dominant. Dominant negative and haploinsufficient mutations described.<ref name="pmid21490157" />
* ALPS-sFAS: Fas. Somatic FAS mutations in DNT compartment.<ref name="pmid15459302" /> 10% of patients
* ALPS-FASL: [[Fas ligand]]. Germline FASL mutations. 3 reported cases
* ALPS-CASP10: [[Caspase 10]]. Germline CASP10 mutation. 2% of patients
* ALPS-U: Undefined. 20% of patients
* CEDS: Caspase 8 deficiency state. No longer considered a subtype of ALPS but distinct disorder
* RALD: [[Neuroblastoma RAS viral oncogene homolog|NRAS]], [[KRAS]]. Somatic mutations in NRAS and KRAS in lympocyte compartment. No longer considered a subtype of ALPS but distinct disesase

==Diagnostic algorithm==
{{confusing|section|date=December 2011}}
Old criteria<ref name="pmid12819469" />
* Required
** Chronic non-malignant lymphoproliferation
** Elevated peripheral blood DNTs
** Defective in vitro Fas mediated apoptosis

New criteria<ref name="pmid20538792" />
*Required
** Chronic non-malignant lymphoproliferation (>6 months lymphadenopathy and/or splenomegaly)
** Elevated peripheral blood DNTs
*Accessory
** Primary Accessory
*** Defective in vitro Fas mediated apoptosis
*** Somatic or germline mutation in ALPS causative gene (FAS, FASL, CASP10)
** Secondary Accessory
*** Elevated biomarkers
**** Plasma sFASL >200pg/ml
**** Plasma IL-10 >20pg/ml
**** Plasma or serum vitamin B12 >1500&nbsp;ng/L
**** Plasma IL-18 >500pg/ml
*** Immunohistochemical findings on biopsy consistent with ALPS as determined by experienced hematopathologist
*** Autoimmune cytopenias and polyclonal hypergammaglobulinemia
*** Family history of ALPS or non-malignant lymphoproliferation
* Definitive diagnosis: Required plus one primary accessory criteria
* Probable diagnosis: Required plus one secondary accessory criteria
* Definitive and Probable ALPS should be TREATED THE SAME and patients counseled that they have ALPS if definitive or probable

==Treatment==
{{prose|section|date=December 2011}}
* Mostly commonly directed at autoimmune disease
* Maybe needed to treat bulky lymphoproliferation
* First line therapies
** [[Corticosteroids]]
*** Very active but toxic with chronic use
** IVIgG
*** Not as effective as in other immune cytopenia syndromes
* Second line therapies
** [[Mycophenolate mofetil]] (cellcept)<ref name="pmid15877736" />
*** Inactivates inosine monophosphate
*** Active in most patients
*** Most studied medicine in clinical trials
*** Some patients have complete resolution of autoimmune disease
*** Some patients have partial responses
*** Some patients relapse
*** Does not affect lymphoproliferation or reduce DNTs
*** Well-tolerated: Side effects: Diarrhea, neutropenia
*** Does not require therapeutic drug monitoring
*** No drug-drug interactions
*** Can cause hypogammaglobulinemia (transient) requiring IVIgG replacement
*** Consider PCP prophylaxis but usually not needed
*** Most commonly used agent in patients who require chronic treatment based on tolerability and efficacy
** [[Sirolimus]] (rapamycin, rapamune)
*** mTOR ([[mammalian target of rapamycin]]) inhibitor<ref name="pmid16757690" />
*** Active in most patients
*** Second most studied agent in clinical trials
*** Most patients have complete resolution of autoimmune disease (>90%)<ref name="pmid19208097" /><ref name="pmid19588524" />
*** Most patients have complete resolution of lymphoproliferation, including lymphadenopathy and splenomegaly (>90%)
*** Some patients have near complete response (disease flares with viral illness)
*** Some patients have partial responses (most commonly patients with non hematologic autoimmune disease)
*** Most patients have elimination of peripheral blood DNTs
*** mTOR/Akt/PI3K pathway may be activated in abnormal ALPS cells: mTOR inhibitors may be targeted therapy
*** May not be as immune suppressive in normal lymphocytes as other agents. Some patients have had improvement in immune function with transition from cellcept to rapamycin<ref name="pmid21475130" />
*** Not reported to cause hypogammaglobulinemia
*** Hypothetically, may have lower risk of secondary cancers as opposed to other immune suppressants
**** Always a risk with any agent in pre-cancerous syndrome as immune suppression can decreased tumor immunosurvellence
**** mTOR inhibitors active against lymphomas, especially EBV+ lymphomas. Thus, THEORETICALLY could eliminate malignant clones.
*** Requires therapeutic drug monitoring
**** Goal serum trough 5-15&nbsp;ng/ml
*** Drug-drug interactions
*** Well tolerated: Side effects: mucositis, diarrhea, hyperlipidemia, delayed wound healing
*** Consider PCP prophylaxis but usually not needed
*** Second most commonly used agent in patients that require chronic therapy.
**** Better activity against autoimmune disease and lymphoproliferation than mycophenolate mofetil and other drugs; however, sirolimus requires therapeutic drug monitoring and can cause mucositis
** Other agents:
*** Fansidar,<ref name="pmid11918552" /><ref name="pmid17674358" /> mercaptopurine: More commonly used in Europe. Good ancedotal data
*** Rituximab: AVOID. Can cause lifelong hypogammaglobulinemia<ref name="pmid19214977" />
*** Splenectomy: AVOID. >30% risk of pneumococcal sepsis even with vaccination and antibiotic prophylaxis<ref name="pmid21885601" /><ref name="pmid21885602" />

==References==
{{Reflist|refs=
<ref name="pmid18193364">{{cite journal |pages=87–92 |doi=10.1007/s12026-007-8001-1 |title=The autoimmune lymphoproliferative syndrome: An experiment of nature involving lymphocyte apoptosis |year=2007 |last1=Fleisher |first1=Thomas A. |journal=Immunologic Research |volume=40 |pmid=18193364 |issue=1}}{{MEDRS|date=December 2011}}</ref>
<ref name="pmid16522544">{{cite journal |pages=15–23 |doi=10.1080/10245330500329094 |title=Causes and consequences of the autoimmune lymphoproliferative syndrome |year=2006 |last1=Rao |first1=V. Koneti |last2=Straus |first2=Stephen E. |journal=Hematology |volume=11 |pmid=16522544 |issue=1}}</ref> 
<ref name="pmid19930184">{{cite journal |pages=205–16 |doi=10.1111/j.1365-2141.2009.07991.x |title=Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS) |year=2010 |last1=Teachey |first1=David T. |last2=Seif |first2=Alix E. |last3=Grupp |first3=Stephan A. |journal=British Journal of Haematology |volume=148 |issue=2 |pmid=19930184 |pmc=2929682}}</ref> 
<ref name="pmid15542578">{{cite journal |pages=2443–8 |doi=10.1182/blood-2004-09-3542 |title=Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS) |year=2005 |last1=Teachey |first1=David T. |journal=Blood |volume=105 |issue=6 |pmid=15542578 |last2=Manno |first2=Catherine S. |last3=Axsom |first3=Kelly M. |last4=Andrews |first4=Timothy |last5=Choi |first5=John K. |last6=Greenbaum |first6=Barbara H. |last7=McMann |first7=Joseph M. |last8=Sullivan |first8=Kathleen E. |last9=Travis |first9=Susan F.}}{{MEDRS|date=December 2011}}</ref>
<ref name="pmid12139944">{{cite journal |pages=21–30 |doi=10.1006/clim.2002.5225 |title=A Composite Picture of TcRα/β<sup>+</sup> CD4<sup>−</sup>CD8<sup>−</sup> T Cells (α/β-DNTCs) in Humans with Autoimmune Lymphoproliferative Syndrome |year=2002 |last1=Bleesing |first1=Jack J.H. |last2=Brown |first2=Margaret R. |last3=Novicio |first3=Cynthia |last4=Guarraia |first4=David |last5=Dale |first5=Janet K. |last6=Straus |first6=Stephen E. |last7=Fleisher |first7=Thomas A. |journal=Clinical Immunology |volume=104 |pmid=12139944 |issue=1}}{{MEDRS|date=December 2011}}</ref>
<ref name="pmid19176318">{{cite journal |pages=3027–30 |doi=10.1182/blood-2008-09-179630 |title=FAS-L, IL-10, and double-negative CD4<sup>−</sup>CD8<sup>−</sup> TCR α/β<sup>+</sup> T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function |year=2009 |last1=Magerus-Chatinet |first1=Aude |last2=Stolzenberg |first2=Marie-Claude |last3=Loffredo |first3=Maria S. |last4=Neven |first4=Bénédicte |last5=Schaffner |first5=Catherine |last6=Ducrot |first6=Nicolas |last7=Arkwright |first7=Peter D. |last8=Bader-Meunier |first8=Brigitte |last9=Barbot |first9=José |journal=Blood |volume=113 |issue=13 |pmid=19176318}}{{MEDRS|date=December 2011}}</ref>
<ref name="pmid20227752">{{cite journal |pages=946–949.e6 |doi=10.1016/j.jaci.2009.12.983 |title=Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome |year=2010 |last1=Caminha |first1=Iusta |last2=Fleisher |first2=Thomas A. |last3=Hornung |first3=Ronald L. |last4=Dale |first4=Janet K. |last5=Niemela |first5=Julie E. |last6=Price |first6=Susan |last7=Davis |first7=Joie |last8=Perkins |first8=Katie |last9=Dowdell |first9=Kennichi C. |journal=Journal of Allergy and Clinical Immunology |volume=125 |issue=4 |pmid=20227752}}{{MEDRS|date=December 2011}}</ref>
<ref name="pmid20068224">{{cite journal |pages=2142–5 |doi=10.1182/blood-2009-08-239525 |title=Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: A multi-institutional study |year=2010 |last1=Seif |first1=A. E. |last2=Manno |first2=C. S. |last3=Sheen |first3=C. |last4=Grupp |first4=S. A. |last5=Teachey |first5=D. T. |journal=Blood |volume=115 |issue=11 |pmid=20068224 }}{{MEDRS|date=December 2011}}</ref> 
<ref name="pmid12819469">{{cite journal |pages=417–21 |doi=10.1097/00002281-200307000-00008 |title=Autoimmune lymphoproliferative syndrome |year=2003 |last1=Sneller |first1=Michael C. |last2=Dale |first2=Janet K. |last3=Straus |first3=Stephen E. |journal=Current Opinion in Rheumatology |volume=15 |issue=4 |pmid=12819469}}</ref>
<ref name="pmid20538792">{{cite journal |pages=e35–40 |doi=10.1182/blood-2010-04-280347 |pmc=2953894 |title=Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): Report from the 2009 NIH International Workshop |year=2010 |last1=Oliveira |first1=J. B. |last2=Bleesing |first2=J. J. |last3=Dianzani |first3=U. |last4=Fleisher |first4=T. A. |last5=Jaffe |first5=E. S. |last6=Lenardo |first6=M. J. |last7=Rieux-Laucat |first7=F. |last8=Siegel |first8=R. M. |last9=Su |first9=H. C. |journal=Blood |volume=116 |issue=14 |pmid=20538792}}</ref>
<ref name="pmid21490157">{{cite journal |pages=6035–43 |doi=10.4049/jimmunol.1100021 |title=FAS Haploinsufficiency is a Common Disease Mechanism in the Human Autoimmune Lymphoproliferative Syndrome |year=2011 |last1=Kuehn |first1=H. S. |last2=Caminha |first2=I. |last3=Niemela |first3=J. E. |last4=Rao |first4=V. K. |last5=Davis |first5=J. |last6=Fleisher |first6=T. A. |last7=Oliveira |first7=J. B. |journal=The Journal of Immunology |volume=186 |issue=10 |pmid=21490157}}{{MEDRS|date=December 2011}}</ref>
<ref name="pmid15459302">{{cite journal |pages=1409–18 |doi=10.1056/NEJMoa040036 |title=Autoimmune Lymphoproliferative Syndrome with SomaticFasMutations |year=2004 |last1=Holzelova |first1=Eliska |last2=Vonarbourg |first2=Cédric |last3=Stolzenberg |first3=Marie-Claude |last4=Arkwright |first4=Peter D. |last5=Selz |first5=Françoise |last6=Prieur |first6=Anne-Marie |last7=Blanche |first7=Stéphane |last8=Bartunkova |first8=Jirina |last9=Vilmer |first9=Etienne |journal=New England Journal of Medicine |volume=351 |issue=14 |pmid=15459302}}{{MEDRS|date=December 2011}}</ref>
<ref name="pmid15877736">{{cite journal |pages=534–8 |doi=10.1111/j.1365-2141.2005.05496.x |title=Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome |year=2005 |last1=Koneti Rao |first1=V. |last2=Dugan |first2=Faith |last3=Dale |first3=Janet K. |last4=Davis |first4=Joie |last5=Tretler |first5=Jean |last6=Hurley |first6=John K. |last7=Fleisher |first7=Thomas |last8=Puck |first8=Jennifer |last9=Straus |first9=Stephen E. |journal=British Journal of Haematology |volume=129 |issue=4 |pmid=15877736}}{{MEDRS|date=December 2011}}</ref>
<ref name="pmid16757690">{{cite journal |pages=1965–71 |doi=10.1182/blood-2006-01-010124 |pmc=1895548 |title=Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS) |year=2006 |last1=Teachey |first1=D. T. |journal=Blood |volume=108 |issue=6 |pmid=16757690 |last2=Obzut |first2=DA |last3=Axsom |first3=K |last4=Choi |first4=JK |last5=Goldsmith |first5=KC |last6=Hall |first6=J |last7=Hulitt |first7=J |last8=Manno |first8=CS |last9=Maris |first9=JM}}{{MEDRS|date=December 2011}}</ref>
<ref name="pmid19208097">{{cite journal |pages=101–6 |doi=10.1111/j.1365-2141.2009.07595.x |pmc=2819393 |title=Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome |year=2009 |last1=Teachey |first1=David T. |last2=Greiner |first2=Robert |last3=Seif |first3=Alix |last4=Attiyeh |first4=Edward |last5=Bleesing |first5=Jack |last6=Choi |first6=John |last7=Manno |first7=Catherine |last8=Rappaport |first8=Eric |last9=Schwabe |first9=Dirk |journal=British Journal of Haematology |volume=145 |pmid=19208097 |issue=1}}{{MEDRS|date=December 2011}}</ref>
<ref name="pmid19588524">{{cite journal |title=Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome |pages=1117–9 |year=2009 |last1=Janić |first1=MD |last2=Brasanac |first2=CD |last3=Janković |first3=JS |last4=Dokmanović |first4=BL |last5=Krstovski |first5=RN |last6=Kraguljac Kurtović |first6=JN |volume=53 |issue=6 |doi=10.1002/pbc.22151 |journal=Pediatric blood & cancer |pmid=19588524}}{{MEDRS|date=December 2011}}</ref>
<ref name="pmid17674358">{{cite journal |title=Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome |pages=1049–55 |pmid=17674358 |doi=10.1002/ajh.21007 |year=2007 |last1=Rao |first1=V. Koneti |last2=Dowdell |first2=Kennichi C. |last3=Dale |first3=Janet K. |last4=Dugan |first4=Faith |last5=Pesnicak |first5=Lesley |last6=Bi |first6=Lilia L. |last7=Hoffmann |first7=Victoria |last8=Penzak |first8=Scott |last9=Avila |first9=Nilo A. |journal=American Journal of Hematology |volume=82 |issue=12}}</ref> 
<ref name="pmid11918552">{{cite journal |pages=176–88 |doi=10.1046/j.1365-2141.2002.03357.x |title=Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: Preliminary results of a clinical cohort study and molecular observations |year=2002 |last1=Van Der Werff Ten Bosch |first1=Jutte |last2=Schotte |first2=Peter |last3=Ferster |first3=Alice |last4=Azzi |first4=Nadira |last5=Boehler |first5=Thomas |last6=Laurey |first6=Genevieve |last7=Arola |first7=Mikko |last8=Demanet |first8=Christian |last9=Beyaert |first9=Rudi |journal=British Journal of Haematology |volume=117 |pmid=11918552 |issue=1}}{{MEDRS|date=December 2011}}</ref>
<ref name="pmid21475130">{{cite journal |pmid=21475130 |year=2011 |last1=Teachey |first1=David T. |title=Autoimmune Lymphoproliferative Syndrome: New Approaches to Diagnosis and Management |volume=9 |issue=3 |pages=233–5 |journal=Clinical Advances in Hematology & Oncology |url=http://www.clinicaladvances.com/index.php/our_publications/hem_onc-article/1956/}}{{MEDRS|date=December 2011}}</ref>
<ref name="pmid19214977">{{cite journal |pages=847–52 |doi=10.1002/pbc.21965 |pmc=2774763 |title=Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS) |year=2009 |last1=Rao |first1=V. Koneti |last2=Price |first2=Susan |last3=Perkins |first3=Katie |last4=Aldridge |first4=Patricia |last5=Tretler |first5=Jean |last6=Davis |first6=Joie |last7=Dale |first7=Janet K. |last8=Gill |first8=Fred |last9=Hartman |first9=Kip R. |journal=Pediatric Blood & Cancer |volume=52 |issue=7 |pmid=19214977}}</ref>
<ref name="pmid21885601">{{cite journal |pages=5741–51 |doi=10.1182/blood-2011-07-325217 |pmc=3228494 |title=How I treat autoimmune lymphoproliferative syndrome |year=2011 |last1=Rao |first1=V. K. |last2=Oliveira |first2=J. B. |journal=Blood |volume=118 |issue=22 |pmid=21885601}}</ref>
<ref name="pmid21885602">{{cite journal |pages=4798–807 |doi=10.1182/blood-2011-04-347641 |title=A survey of 90 patients with autoimmune lymphoproliferative syndrome related to ''TNFRSF6'' mutation |year=2011 |last1=Neven |first1=Bénédicte |last2=Magerus-Chatinet |first2=Aude |last3=Florkin |first3=Benoit |last4=Gobert |first4=Delphine |last5=Lambotte |first5=Olivier |last6=De Somer |first6=Lien |last7=Lanzarotti |first7=Nina |last8=Stolzenberg |first8=Marie-Claude |last9=Bader-Meunier |first9=Brigitte |journal=Blood |volume=118 |issue=18 |pmid=21885602}}</ref>
}}

[[Category:Lymphocytic immune system disorders]]
[[Category:RASopathies]]